Literature DB >> 6420041

Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancer.

H W Herr, E L Kleinert, N M Relyea, W F Whitmore.   

Abstract

The polyamines, putrescine, spermidine, and spermine, are fundamentally related to both normal and neoplastic cell proliferation. The prostate gland and prostatic tumors in man and rodents contain large amounts of polyamines. This suggests that inhibition of polyamine biosynthetic enzymes, ornithine decarboxylase (ODC) and S-adenosyl-methionine decarboxylase (SAMDC) may retard the growth of prostatic cancer. Since alpha-difluoromethylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG) are irreversible and competitive inhibitors of ODC and SAMDC, respectively, they were tested as single agents and in combination on a transplantable rapidly growing and hormone-resistant G subline of the Dunning R-3327 rat prostatic adenocarcinoma. Groups of rats bearing tumors were treated with various regimens of DFMO, MGBG, and DFMO plus MGBG, daily for 21 days. Analysis of differences in tumor growth between treatment groups and controls showed DFMO had no antitumor effect but was well tolerated, MGBG retarded growth rate significantly but resulted in drug deaths in over 50% of the animals, and the combination of DFMO and MGBG resulted in rapid decline in tumor growth rates after 5 to 9 days of treatment with reduced toxicity. At 21 days, or death, 38 of 60 (63%) rats had no viable tumor on histologic study, whereas tumor was present in each of the animals in the other groups. Alpha-difluoromethylornithine increased the intracellular uptake of MGBG and potentiated the antigrowth activity of MGBG on a hormone refractory rat prostatic tumor with less toxicity than MGBG alone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420041     DOI: 10.1002/1097-0142(19840315)53:6<1294::aid-cncr2820530612>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.

Authors:  J A Ajani; D M Ota; V B Grossie; J L Abbruzzese; J S Faintuch; Y Z Patt; D E Jackson; B Levin; K Nishioka
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Enhanced antitumor efficacy with a combination of hyperthermochemotherapy and thermosensitization with polyamine antimetabolites in nude mice.

Authors:  S Fujimoto; R D Shrestha; M Ohta; K Igarashi; F Endoh; M Kokubun; S Koike; Y Togawa; K Okui
Journal:  Jpn J Surg       Date:  1987-03

3.  Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor.

Authors:  A M Maddox; M J Keating; K E McCredie; E Estey; E J Freireich
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 4.  The Emerging Clinical Role of Spermine in Prostate Cancer.

Authors:  Qiang Peng; Christine Yim-Ping Wong; Isabella Wai-Yin Cheuk; Jeremy Yuen-Chun Teoh; Peter Ka-Fung Chiu; Chi-Fai Ng
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 5.  Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases.

Authors:  Nicole LoGiudice; Linh Le; Irene Abuan; Yvette Leizorek; Sigrid C Roberts
Journal:  Med Sci (Basel)       Date:  2018-02-08

6.  Combined use of alpha-difluoromethylornithine and an inhibitor of S-adenosylmethionine decarboxylase in mice bearing P388 leukemia or Lewis lung carcinoma.

Authors:  S Nakaike; K Kashiwagi; K Terao; K Iio; K Igarashi
Journal:  Jpn J Cancer Res       Date:  1988-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.